IRINOTECAN ARROW 20 mg/ml, concentrate for solution for infusion bottle, 5 ml
Active ingredients: Irinotecan hydrochloride trihydrate, Irinotecan
Commercialized according to BDPMDispensing in France: Prescription only
Concentrate for solution for infusionbottle, 5 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IRINOTECAN ARROW 20 mg/ml, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre brun de 5 ml
- Marketing authorisation holder
- EUGIA PHARMA (MALTA) (MALTE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Jan 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66782833CIP75729349CIP133400957293499Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE D'IRINOTÉCAN TRIHYDRATÉsolution | 20,00 mg · 1 ml | SA |
| IRINOTÉCANsolution | 17,33 mg · 1 ml | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.